Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 177

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 177
---
 2021 Plan, as well as        
 any automatic increases in the number of shares of our common stock reserved for future issuance under this plan; and |

| • |     | 844,059 shares of common stock reserved for issuance pursuant to future awards under our 2021 Employee Stock                                
 Purchase Plan, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this plan. |

- 115 -

THE ADC PROGRAMS Overview We are a precision oncology company making bold choices in applying technology to efficiently deliver improved therapies for people living with difficult-to-treat cancers. We have deep experience in chemistry, formulation, and drug delivery, as well as research, clinical, and commercial pharmaceutical development, successfully taking product candidates from the clinic to approval, launch, and commercialization. We recently entered into an intellectual property license agreement (the “License Agreement”) with WuXi Biologics (Shanghai FX) Co., Ltd. (“WuXi Biologics”) for the development and global commercialization of a portfolio of three next generation antibody drug conjugates (“ADCs”) targeting clinically validated, broadly overexpressed tumor antigens in high potential cancer indications with significant unmet need. See the section entitled “ THE PIPE FINANCING AND LICENSE AGREEMENT — The License Agreement.” These ADCs are constructed utilizing an advanced linker-payload platform called CPT113 that has been shown to provide high stability in blood circulation and deliver targeted release of a Topoisomerase I (“TOPO1”) inhibitor payload into cancer cells. These in-licensedassets originated through the collaborative efforts of WuXi Biologics, a leading global contract research, development and manufacturing organization (“CRDMO”), and Hangzhou DAC Biotechnology (“Hangzhou DAC”), a global leader in ADC innovation, where Hangzhou DAC’s CPT113 linker-payload has been conjugated to novel antibodies developed by WuXi Biologics against three tumor targets: Protein Tyrosine Kinase 7 (“PTK7”), Mucin 16 (“MUC16”) and Seizure-relatedProtein 6 (“SEZ6”). We believe the resulting ADCs will be able to target cancers expressing these respective tumor markers precisely and deliver the potent, cytotoxic TOPO1 inhibitor at the site of cancer. Each of these ADCs have demonstrated tumor cell binding, tumor cell line cytotoxicity, and in vivoantitumor activity in preclinical models mimicking tumor progression. We anticipate submitting three investigational new drug (“IND”) applications